Rothschild Capital Partners’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-47,117
Closed -$6.87M 59
2017
Q3
$6.87M Sell
47,117
-3,797
-7% -$517K 2.96% 11
2017
Q2
$6.61M Hold
50,914
2.51% 15
2017
Q1
$6.33M Buy
50,914
+10,550
+26% +$1.26M 2.47% 16
2016
Q4
$4.67M Sell
40,364
-1,596
-4% -$178K 1.99% 22
2016
Q3
$4.39M Buy
+41,960
New +$4.54M 1.58% 24
2016
Q2
Sell
-2,000
Closed -$200K 90
2016
Q1
$200K Sell
2,000
-1,110
-36% -$114K 0.09% 62
2015
Q4
$372K Buy
3,110
+200
+7% +$23.1K 0.19% 34
2015
Q3
$315K Buy
2,910
+1,150
+65% +$143K 0.16% 36
2015
Q2
$204K Sell
1,760
-240
-12% -$27.4K 0.09% 45
2015
Q1
$231K Buy
+2,000
New +$239K 0.1% 39

Other funds holding CELG

Rothschild Capital Partners's CELG Position: Q4 2017 in Review

Rothschild Capital Partners sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 47,117 shares — an estimated $6.87M sold.

Rothschild Capital Partners first reported a position in CELG in Q1 2015 and held it in 10 quarters. The position peaked at $6.87M in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Rothschild Capital Partners reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Rothschild Capital Partners sold 47,117 Celgene Corp shares in Q4 2017, an estimated $6.87M.
  • Rothschild Capital Partners first reported a position in Celgene Corp in Q1 2015 and held it in 10 quarters.
  • Rothschild Capital Partners's Celgene Corp position peaked at $6.87M in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Rothschild Capital Partners's 13F filing for Q4 2017, filed 31 Jan 2018.